Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822575 | 1.00 | F10 (0.42) | F10F2PRSS1MTNR1AMTNR1B | |
| SCHEMBL25017971 | 0.89 | F10 (0.43) | F10F2PRSS1MCL1BCL2 | |
| SCHEMBL31689685 | 0.81 | F10 (0.53) | F10F2MCL1 | |
| SCHEMBL21822223 | 0.81 | F10 (0.53) | F10F2MCL1 | |
| SCHEMBL21822614 | 0.81 | F10 (0.60) | F10F2PRSS1 | |
| SCHEMBL31689644 | 0.81 | F10 (0.60) | F10F2PRSS1 | |
| SCHEMBL25015975 | 0.78 | F10 (0.46) | F10F2PRSS1MCL1 | |
| SCHEMBL21822244 | 0.78 | F10 (0.54) | F10F2PRSS1 | |
| SCHEMBL21822365 | 0.77 | F10 (0.50) | F10F2PRSS1 | |
| SCHEMBL25016213 | 0.76 | RHEB (0.47) | F10F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | F10 1548/4885F2 408/4885PRSS1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.